Regeneron’s $490M Volume Ranks 236th in Liquidity as Shares Slip 0.13% Amid FDA Anticipation

On September 10, 2025, , ranking 236th among stocks in terms of liquidity. , reflecting subdued investor activity amid a mixed broader market.

. While no major clinical trial updates were announced for Regeneron’s pipeline this week, . .

, . , reinforcing near-term consolidation patterns.

To evaluate the performance of high-volume stocks, a back-test would require defining: (1) universe parameters (e.g., NYSE/NASDAQ-listed equities); (2) weighting methodology (equal-weighted by default); (3) entry/exit price conventions; (4) transaction cost assumptions; and (5) inclusion of delisted securities. , volatility, , 2022, , 2025.